Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma.

Majeti BK, Lee JH, Simmons BH, Shojaei F.

BMC Cancer. 2013 Apr 29;13:213. doi: 10.1186/1471-2407-13-213.


Supratentorial metastatic enteropathy-associated T-cell lymphoma: A case report and literature review.

Defillo A, Zelensky A, Simmons BH, Nussbaum ES.

Surg Neurol Int. 2012;3:144. doi: 10.4103/2152-7806.103887. Epub 2012 Nov 27.


Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.

Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F.

Cancer Chemother Pharmacol. 2012 Aug;70(2):213-20. doi: 10.1007/s00280-012-1899-6. Epub 2012 Jun 9.


Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E.

J Exp Clin Cancer Res. 2012 Mar 23;31:26. doi: 10.1186/1756-9966-31-26.


HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.

Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG.

Cancer Lett. 2012 Jul 1;320(1):48-55. doi: 10.1016/j.canlet.2012.01.026. Epub 2012 Jan 21.


Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.

Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson TA, Simmons BH, Lippincott J, Casperson GF, Levin WJ, Stampino CG, Shalinsky DR, Ferrara KW, Fiedler W, Bertolini F.

Cancer Res. 2011 Feb 15;71(4):1362-73. doi: 10.1158/0008-5472.CAN-10-1451. Epub 2011 Jan 6.


HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.

Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG.

Cancer Res. 2010 Dec 15;70(24):10090-100. doi: 10.1158/0008-5472.CAN-10-0489. Epub 2010 Oct 15.


Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.

Humphries PS, Bailey S, Almaden JV, Barnum SJ, Carlson TJ, Christie LC, Do QQ, Fraser JD, Hess M, Kellum J, Kim YH, McClellan GA, Ogilvie KM, Simmons BH, Skalitzky D, Sun S, Wilhite D, Zehnder LR.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6120-3. Epub 2006 Sep 14.


Mucoepidermoid carcinoma involving Warthin tumor. A report of five cases and review of the literature.

Williamson JD, Simmons BH, el-Naggar A, Medeiros LJ.

Am J Clin Pathol. 2000 Oct;114(4):564-70. Review.


A 67-year-old woman with gastrointestinal hemorrhage and chronic hepatitis.

Simmons BH, Gaglio P, Daroca PJ, Gerber MA.

J La State Med Soc. 1997 Dec;149(12):485-9.


An 82-year-old woman with carcinomatosis.

Simmons BH, Meleg-Smith S.

J La State Med Soc. 1996 Jun;148(6):245-7.


Supplemental Content

Loading ...
Support Center